Drug Companies

Also showing items for Drug Research

 
Stock Quotes for Drug Companies top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 524689 investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for ankurdrugs investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for pdpl investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 530317 investment picks
  • Industry: Chemicals
  • Sector: Basic Materials
  • Stock Style: Small Value
Sign-up for 532637 investment picks

 
News Articles for Drug Companies top ^
PRINCETON, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS) , a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Sign-up for Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer investment picks
NATICK, Mass., May 20, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that its lead drug candidate, Selinexor (KPT-330), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Sign-up for Karyopharm Announces Second Orphan Drug Designation for Selinexor in Diffuse Large B-Cell Lymphoma (DLBCL) investment picks
REDWOOD CITY, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer.
Sign-up for OncoMed Receives Orphan Drug Designation From the FDA for Demcizumab in Pancreatic Cancer investment picks
SAN DIEGO , May 13, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that the U.S. Office of Orphan Products Development at the Food and Drug Administration (FDA) has approved the transfer of sponsorship of the Orphan Drug Designation for intrathecal resiniferatoxin (RTX) in the treatment of intractable pain in end-stage disease from the National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research to Sorrento.
Sign-up for Sorrento Announces Transfer of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin from NIH investment picks
LEXINGTON, Massachusetts , May 16, 2014 /PRNewswire/ -- FDA submission planned for 1 st Quarter 2015 Shire forms business unit focused in ophthalmics Following a May 15, 2014 , meeting with the U.S. Food and Drug Administration (FDA), Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
Sign-up for Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults investment picks
LEXINGTON, Massachusetts , May 19, 2014 /PRNewswire/ -- FDA submission planned for 1 st Quarter 2015 Shire forms business unit focused in ophthalmics Following a May 15, 2014 , meeting with the U.S. Food and Drug Administration (FDA), Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
Sign-up for Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults investment picks
NEW YORK (MarketWatch) -- The U.S. Food and Drug Administration has approved a new drug by Merck (MRK) that lowers the risk of heart attacks and cardiovascular events associated with peripheral arterial disease in patients who have survived such cardiovascular trauma.
Sign-up for UPDATE: FDA approves Merck's heart-attack prevention drug investment picks
NEW YORK (MarketWatch) -- The U.S. Food and Drug Administration has approved a new drug by Merck (MRK) that lowers the risk of heart attacks and cardiovascular events associated with peripheral arterial disease.
Sign-up for FDA approves Merck's heart-attack prevention drug investment picks
IBM Analytics and Mobile Solutions Will Ensure Medicine Availability LUSAKA, Zambia , May 22, 2014 /PRNewswire/ -- IBM (NYSE: IBM ) today announced a collaboration with the Zambian Ministry of Health to provide citizens with improved access to 200 life saving drugs.
Sign-up for Zambian Government and IBM Provide Improved Access to Life Saving Drugs investment picks
2014/5/15
TORONTO , May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes.
Sign-up for Transition Therapeutics Diabetes Drug Candidate, TT-401, Commences Phase 2 Clinical Study investment picks
AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif.
Sign-up for AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Drug Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Drive Growth  |  Next: Drug Delivery Shares